Publication | Closed Access
Copper(II) Complexes of Halogenated Quinoline Schiff Base Derivatives Enabled Cancer Therapy through Glutathione-Assisted Chemodynamic Therapy and Inhibition of Autophagy Flux
71
Citations
50
References
2022
Year
Twelve new complexes <b>Cu(L<sup>1</sup>)<sub>2</sub></b>-<b>Cu(L<sup>12</sup>)<sub>2</sub></b> were designed and synthesized to improve their chemotherapeutic properties. They showed considerable antiproliferative activity against T24 cancer cells but lower cytotoxicity to human normal cells HL-7702 and WI-38. A mechanism study indicated that <b>Cu(L<sup>4</sup>)<sub>2</sub></b> and <b>Cu(L<sup>10</sup>)<sub>2</sub></b> were reduced to Fenton-like Cu<sup>+</sup> by glutathione depletion, and the resulting Cu<sup>+</sup> catalyzed the generation of highly toxic hydroxyl radicals from excess H<sub>2</sub>O<sub>2</sub>. Simultaneously, <b>Cu(L<sup>4</sup>)<sub>2</sub></b> and <b>Cu(L<sup>10</sup>)<sub>2</sub></b> could decrease the catalase activity to restrain H<sub>2</sub>O<sub>2</sub> transfer to H<sub>2</sub>O for enhanced chemodynamic therapy (CDT). These induced mitochondrial dysfunctions and endoplasmic reticulum stress to induce T24 cell apoptosis. In addition, <b>Cu(L<sup>4</sup>)<sub>2</sub></b> and <b>Cu(L<sup>10</sup>)<sub>2</sub></b> inhibited autophagy flux to promote cell apoptosis. <b>Cu(L<sup>4</sup>)<sub>2</sub></b> and <b>Cu(L<sup>10</sup>)<sub>2</sub></b> demonstrated strong tumor inhibition ability in the T24 xenograft model. Moreover, <b>Cu(L<sup>10</sup>)<sub>2</sub></b> showed higher antitumor activity and a better safety profile than the CDT agent <b>Cu1</b>. <b>Cu(L<sup>10</sup>)<sub>2</sub></b> exhibited excellent pharmacokinetic properties. Collectively, <b>Cu(L<sup>4</sup>)<sub>2</sub></b> and <b>Cu(L<sup>10</sup>)<sub>2</sub></b> could be developed as potential CDT candidates for cancer treatment.
| Year | Citations | |
|---|---|---|
Page 1
Page 1